Metformin has been the cornerstone of Type 2 diabetes treatment for over 60 years. With newer, more glamorous medications capturing headlines, it is worth examining what metformin still does exceptionally well — and where its limitations lie.
Why Metformin Has Remained First-Line for Decades
Metformin’s durability as first-line therapy is based on an impressive evidence base. The landmark UKPDS (United Kingdom Prospective Diabetes Study) demonstrated that metformin reduces cardiovascular mortality in overweight people with Type 2 diabetes — a benefit that has not been clearly demonstrated for many newer medications. It is also the only oral diabetes medication with evidence of cancer risk reduction, particularly for colorectal and breast cancer.
Its practical advantages are equally compelling: it is inexpensive, widely available, does not cause hypoglycaemia when used alone, does not cause weight gain (and may modestly reduce weight), and has a well-understood safety profile built over decades of use in hundreds of millions of patients.
Metformin vs Newer Medications
| Factor | Metformin | SGLT2 Inhibitors | GLP-1 Agonists |
|---|---|---|---|
| HbA1c reduction | 1.0–1.5% | 0.5–1.0% | 1.0–2.0% |
| Weight effect | Neutral/slight loss | Modest loss (2–3kg) | Significant loss (4–15kg) |
| Cardiovascular benefit | Yes (UKPDS) | Yes (heart failure, CKD) | Yes (MACE reduction) |
| Cost | Very low | High | Very high |
| Hypoglycaemia risk | Very low | Very low | Low |
ℹ️ When Metformin Is Not Appropriate
Metformin is contraindicated in people with significantly reduced kidney function (eGFR below 30 ml/min/1.73m²) due to the risk of lactic acidosis. It should be used with caution in people with eGFR 30–45. Gastrointestinal side effects (nausea, diarrhoea) affect up to 30% of users; the extended-release formulation is better tolerated and should be tried before discontinuing treatment.
✅ Key Takeaway
Metformin remains an excellent first-line treatment for most people with Type 2 diabetes, offering proven cardiovascular benefits, a strong safety record, and very low cost. For people with established cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors or GLP-1 agonists may be preferred as first or second-line agents. The best treatment plan is always individualised.
English 
Urdu